Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib in Pre-Surgical Advanced Melanoma
NCT01701037Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jan 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma, sponsored by Vanderbilt-Ingram Cancer Center. Started Jan 2013; status: terminated.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01701037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01701037.